These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 32602248)

  • 1. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.
    Tan G; Chu C; Gui X; Li J; Chen Q
    Medicine (Baltimore); 2018 Mar; 97(13):e0197. PubMed ID: 29595655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 4. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application.
    Casas-Arozamena C; Vilar A; Cueva J; Arias E; Sampayo V; Diaz E; Oltra SS; Moiola CP; Cabrera S; Cortegoso A; Curiel T; Abalo A; Pamies Serrano M; Domingo S; Padilla-Iserte P; Arnaez de la Cruz M; Hernández A; García-Pineda V; Ruiz-Bañobre J; López R; Matias-Guiu X; Colás E; Gil-Moreno A; Abal M; Moreno-Bueno G; Muinelo-Romay L
    J Exp Clin Cancer Res; 2024 Sep; 43(1):264. PubMed ID: 39304963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
    Giro C; Yamada AMTD; Cruz FJSM; do R Barros LA; da C A Alves B; Fonseca FLA; Del Giglio A
    Breast Cancer Res Treat; 2024 Jul; 206(2):329-335. PubMed ID: 38743176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free DNA concentration in patients with clinical or mammographic suspicion of breast cancer.
    Peled M; Agassi R; Czeiger D; Ariad S; Riff R; Rosenthal M; Lazarev I; Novack V; Yarza S; Mizrakli Y; Douvdevani A
    Sci Rep; 2020 Sep; 10(1):14601. PubMed ID: 32884019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Vesicle DNA Extraction and Sequencing in Ancient Serum Samples From Patients With Breast Cancer.
    Heidinger M; Egle D; Piscuoglio S; Navarro-Aguadero MÁ; Sánchez S; Hergueta-Redondo M; Gallardo M; Barrio S; García-Peláez B; Molina-Vila MA; Maggi N; Eller RS; Loesch JM; Alborelli I; Peinado H; Weber W; Weber WP
    Anticancer Res; 2024 Jul; 44(7):2981-2988. PubMed ID: 38925824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
    Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
    Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
    Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
    Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study.
    Ritter M; Paradiso V; Widmer P; Garofoli A; Quagliata L; Eppenberger-Castori S; Soysal SD; Muenst S; Ng CKY; Piscuoglio S; Weber W; Weber WP
    Clin Breast Cancer; 2020 Oct; 20(5):413-421.e1. PubMed ID: 32650988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients.
    Lin S; Wang S; Xu B
    J Cancer Res Ther; 2024 Apr; 20(2):563-569. PubMed ID: 38454812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
    Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
    Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
    Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
    Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh HE; Kim YS
    Medicine (Baltimore); 2018 Oct; 97(42):e12862. PubMed ID: 30334995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.